Monopar Therapeutics' (MNPR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Monopar Therapeutics (MNPR), indicating a cautious outlook on the stock.
• Several brokerages have issued varying ratings on Monopar, with targets ranging from $60.00 to $115.00, and a consensus rating of "Moderate Buy" with a target price of $97.33.
• Insider selling has been significant, with over 592,733 shares sold by company executives in the last three months, raising concerns about management's confidence in the stock.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "sell (d-)" rating reissued by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

A number of other brokerages have also commented on MNPR. Chardan Capital raised their price target on Monopar Therapeutics from $60.00 to $85.00 and gave the stock a "buy" rating in a research note on Thursday, September 25th. Lake Street Capital assumed coverage on Monopar Therapeutics in a report on Tuesday, September 23rd. They set a "buy" rating and a $106.00 price target on the stock. HC Wainwright set a $105.00 price target on Monopar Therapeutics and gave the stock a "buy" rating in a research note on Monday, September 29th. Oppenheimer set a $115.00 price target on shares of Monopar Therapeutics and gave the stock an "outperform" rating in a research note on Thursday, October 2nd. Finally, BTIG Research upped their price target on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Monopar Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.33.

Monopar Therapeutics Stock Up 0.1%

NASDAQ MNPR opened at $98.57 on Wednesday. Monopar Therapeutics has a 52 week low of $4.50 and a 52 week high of $105.00. The company has a market cap of $608.18 million, a PE ratio of -29.60 and a beta of 1.42. The firm's 50-day simple moving average is $51.98 and its two-hundred day simple moving average is $42.49.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, equities research analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity at Monopar Therapeutics

In related news, Director Kim R. Tsuchimoto sold 8,904 shares of the company's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the completion of the sale, the director owned 11,486 shares in the company, valued at $459,440. This represents a 43.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Chandler Robinson sold 16,800 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the transaction, the chief executive officer owned 73,472 shares of the company's stock, valued at approximately $2,938,880. The trade was a 18.61% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 592,733 shares of company stock worth $36,700,227. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Monopar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Gerber LLC acquired a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $204,000. AlphaQuest LLC purchased a new position in Monopar Therapeutics in the first quarter valued at about $44,000. Affinity Asset Advisors LLC purchased a new position in Monopar Therapeutics in the 1st quarter worth approximately $2,257,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Monopar Therapeutics during the first quarter worth about $328,000. Finally, Goldman Sachs Group Inc. acquired a new position in Monopar Therapeutics in the first quarter worth about $673,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.